Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent
Autor: | A. Raven, E.G.V. Evans, N.R. Rowell, Mark Goodfield, R.A. Forster |
---|---|
Rok vydání: | 1989 |
Předmět: |
Adult
Male medicine.medical_specialty Antifungal Agents Time Factors Exacerbation medicine.medical_treatment Administration Oral Hand Dermatoses Dermatology Naphthalenes medicine.disease_cause law.invention Randomized controlled trial Oral administration law Onychomycosis medicine Humans Dyspepsia skin and connective tissue diseases Terbinafine Mycosis Aged Randomized Controlled Trials as Topic Foot Dermatoses Chemotherapy integumentary system business.industry Middle Aged medicine.disease body regions Clinical trial Dermatophyte Female business medicine.drug |
Zdroj: | British Journal of Dermatology. 121:753-757 |
ISSN: | 0007-0963 |
DOI: | 10.1111/j.1365-2133.1989.tb08217.x |
Popis: | We report on the use of a new orally active fungicidal agent, terbinafine (SF 86-327, Lamisil) in the treatment of patients with dermatophyte onychomycosis. Twenty patients with toe-nail, and 10 with finger-nail infection received 250 mg of terbinafine daily: finger-nail infections were treated for 6 months and toe-nail infections for 12 months. All 24 patients who completed the course of therapy achieved mycological cure, as did two subjects who dropped out of the trial. All but two patients had clinically normal nails at the end of the study period. The mean time for mycological cure was 12.5 weeks for finger-nail infection, and 24 weeks for toe-nail infections. The time for a clinical cure with normal nails was 20.5 weeks for finger-nail infection, and 44 weeks for toe-nail infection. An exacerbation of pre-existing dyspepsia occurred in three of the six patients who did not complete the trial but there were no other significant adverse reactions. |
Databáze: | OpenAIRE |
Externí odkaz: |